Medicare for All? Benefits of Part D Model Come Into Sharper Focus for Pharma
This article was originally published in RPM Report
Medicare’s drug spending grew more than 7% in 2012, according to the latest government statistics. If only the rest of the market worked like Part D.
You may also be interested in...
A proposed Medicare rule says under new criteria CMS has developed, antidepressants and immunosuppressants will no longer be protected classes in plan formularies, but antineoplastics, antiretrovirals and anticonvulsants will remain. Antipsychotics will also be protected through 2015 as CMS continues to evaluate the class.
Implementation of the Affordable Care Act in 2014 will help significantly increase growth for pharma. The increase won’t be as big as it might have been, thanks to the Supreme Court ruling allowing states to opt out of Medicaid expansion, but it should still be a significant acceleration.
There may be significant savings from eliminating wasteful packaging for high cost specialty drugs. The US FDA, however, is urging policy makers not to overlook the importance of patient safety in packaging issues.